Drug Trial News

RSS

Phase 1b trial validates efficacy of Pulmatrix PUR118 to treat COPD

Pulmatrix, Inc., a clinical stage biotechnology company creating novel inhaled therapeutics, today announced top line results from a clinical study showing that the novel inhaled therapeutic, PUR118, demonstrated anti-inflammatory efficacy and was well-tolerated in two Phase 1b studies in patients with chronic obstructive pulmonary disease (COPD).

5 Sep 2012

ImmusanT commences Nexvax2 clinical trials for celiac disease in New Zealand, Australia and the U.S.

ImmusanT announced today that it has initiated clinical trials in New Zealand, Australia and the U.S. to evaluate Nexvax2, the first therapeutic vaccine for patients with celiac disease. Nexvax2 is designed to re-establish patients' tolerance to the toxic effects of gluten, a protein in wheat, barley and rye, and allow them to return to a normal diet.

5 Sep 2012

AlloCure commences AC607 Phase 2 clinical trial for acute kidney injury

AlloCure, Inc. today announced that it has initiated a phase 2 clinical trial of AC607, the company's mesenchymal stem cell therapy, as a potential treatment for acute kidney injury.

5 Sep 2012

Avanir initiates enrollment in AVP-923 Phase II clinical trial for treatment of agitation in AD patients

Avanir Pharmaceuticals, Inc. today announced the enrollment of the first patient in study AVR-131. The study is a Phase II clinical trial investigating the use of AVP-923 for the treatment of agitation in patients with Alzheimer's disease.

5 Sep 2012

KYTHERA completes enrollment in ATX-101 Phase III trials for reduction of submental fat

KYTHERA Biopharmaceuticals, Inc. today announced the completion of enrollment in two pivotal U.S. and Canadian Phase III clinical trials of ATX-101, a potential first-in-class injectable facial aesthetic drug under clinical investigation for the reduction of submental fat, which commonly presents as an undesirable "double chin." KYTHERA expects to release top-line results in mid-2013.

4 Sep 2012

Biokine, BioLineRx sign license agreement to develop and commercialize BL-8040 for AML

BioLineRx Ltd., a biopharmaceutical drug development company, announced today that it has signed an exclusive, worldwide license agreement with Biokine Therapeutics Ltd., a Clal Biotechnology Industries portfolio company, for the development and commercialization of BL-8040 (formerly BKT-140), a Phase II ready drug candidate for the treatment of acute myeloid leukemia (AML), as well as other types of hematological cancer.

4 Sep 2012

Data from ESTEVE’s S1RA E-52862 Phase I trial programme on pain

ESTEVE announces the recent publication of data from the Phase I clinical trial programme of a novel, highly potent and selective, once-daily, S1RA E-52862, developed by the ESTEVE R&D team, in the British Journal of Clinical Pharmacology.

4 Sep 2012

Infliximab may offer new hope for people with difficult-to-treat depression

Researchers at Emory University have found that a medication that inhibits inflammation may offer new hope for people with difficult-to-treat depression. The study was published Sept. 3 in the online version of Archives of General Psychiatry.

4 Sep 2012

High-dose vitamin D appears to help patients with TB recover more quickly

For decades before antibiotics became generally available, sunshine was used to treat tuberculosis, with patients often being sent to Swiss clinics to soak up the sun's healing rays. Now, for the first time scientists have shown how and why heliotherapy might, indeed, have made a difference.

4 Sep 2012

New analyses from Esbriet RECAP study in IPF patients presented at ERS 2012

InterMune, Inc. announced that new analyses of data from the RECAP extension study of Esbriet (pirfenidone) were presented today at the 2012 Annual Congress of the European Respiratory Society (ERS) in Vienna, Austria by Dr. Ulrich Costabel of the Ruhrlandklinik, Essen, Germany.

3 Sep 2012

Inhaled steroid drugs slow growth in children with asthma

Children who use inhaled steroid drugs for asthma end up slightly shorter at their full adult height than children who don't use the drugs, new results from a comprehensive asthma study show.

3 Sep 2012

Combining tiotropium with olodaterol significantly improves lung function in COPD patients

New phase II data presented for the first time today at the 2012 European Respiratory Society (ERS) congress show that combining tiotropium with olodaterol significantly improved lung function (FEV1) over 24 hours in COPD patients compared to olodaterol alone.

3 Sep 2012

Boehringer Ingelheim announces data from olodaterol plus tiotropium Phase II COPD study

Boehringer Ingelheim presented today for the first time data from a Phase II dose ranging study investigationg the combination of olodaterol, an investigational long-acting beta2-agonist (LABA), and tiotropium, a long-acting muscarinic antagonist (LAMA), in COPD patients, compared to the investigational agent olodaterol alone.

3 Sep 2012

Tiotropium improves lung function in symptomatic asthma patients on ICS/LABA

Data from the PrimoTinA-asthma Phase III studies presented for the first time today at the 2012 European Respiratory Society (ERS) congress show that tiotropium significantly reduced asthma exacerbations in patients who remain symptomatic despite treatment with at least ICSB/LABAC.

3 Sep 2012

Sosei highlights data from QVA149 clinical trials on COPD

Sosei Group Corporation highlights that further data from the once-daily chronic obstructive pulmonary disease (COPD) clinical trial programs were presented today by Novartis at the European Respiratory Society (ERS) Congress.

3 Sep 2012

First data from Boehringer Ingelheim’s Respimat Phase III asthma program

Boehringer Ingelheim presented today the first data from the Phase III UniTinA-asthma program. In two studies, presented at the 2012 European Respiratory Society (ERS) Congress in Vienna, Austria, tiotropium delivered once daily via the Respimat inhaler significantly improved lung function and reduced asthma exacerbations in patients who remained symptomatic on current treatment with at least high dose inhaled corticosteroids (ICS) and long-acting beta agonists (LABA).

3 Sep 2012

SPIRIVA to mark 10th anniversary with European Respiratory Society Congress

Coinciding with the annual European Respiratory Society Congress, ERS 2012, SPIRIVA (tiotropium), the first once-daily long-acting inhaled anticholinergic maintenance treatment for patients with Chronic Obstructive Pulmonary Disease (COPD) will mark its 10th anniversary since launch.

3 Sep 2012

Positive results from Elevation Pharmaceuticals’ EP-101 Phase 2b study on COPD

Elevation Pharmaceuticals, Inc. today presented positive efficacy and safety results from the GOLDEN-1 study – a Phase 2b study evaluating EP-101 in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) – at the annual meeting of the European Respiratory Society in Vienna, Austria.

3 Sep 2012

Sophiris announces data from PRX302 transrectal safety study on Benign Prostatic Hyperplasia

Sophiris Bio Inc. today announced data from its transrectal safety study, in which PRX302, the company's drug candidate for the treatment of Benign Prostatic Hyperplasia (BPH or enlarged prostate), was well tolerated through three months following a transrectal injection.

1 Sep 2012

GenSpera plans to initiate G-202 Phase II trial in prostate cancer

GenSpera, Inc. announced that the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom (UK) has cleared for initiation a Phase II human clinical trial of its lead compound, G-202, in the treatment of prostate cancer patients who have failed prior hormonal therapy.

1 Sep 2012